Sonavex, a Maryland-based medical device company, has secured $15 million Series A2 round to advance the development of its diagnostic and health monitoring devices.
The company’s investment was supported by existing and new investors, including GenHenn Capital, Unorthodox Ventures, JSTAR Capital, Riptide Ventures, Partners Investment and Oakwood Circle Ventures.
According to a news report by Medicaldevice Network, Sonavex plans to use part of the new investments to further develop EchoSure and EchoMark, which are designed to enable healthcare providers to collect critical data in dialysis clinics. This data can then be used to assess arteriovenous fistula maturation.
Sonavex’s Echomark is the world’s first automated ultrasound marker developed for blood vessels. The technology helps healthcare teams quantify and visualize vital clinical data. Its unique Geometry allows healthcare professionals to collect and view critical information such as quantitative flow and morphology without precise probe orientation, parameter tuning, or positioning.
On the other hand, Echosure is designed to automatically detect volumetric flow, depth, and diameter. In combination, the two patented technologies allow any member of the clinical team to collect critical information about arteriovenous fistula, including volumetric flow, depth, and diameter.
Sonavex completed its first clinical study to evaluate the effectiveness of the technology in January 2024. The study focused on evaluating the effectiveness of EchoMark and EchoSure in improving the results for AV fistula maturation assessments for patients undergoing dialysis.
The study’s promising results led to the approval of the technologies by the US Food and Drug Administration (FDA) under investigative device designation for the MAFASA trial.
